Niagen Bioscience (NAGE) Non Operating Income (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Non Operating Income of $375000.0 for Q1 2026, down 18.3% year-over-year from $459000.0 in Q1 2025, and up 10.95% quarter-over-quarter from $338000.0 in Q4 2025.
Niagen Bioscience (NAGE) Non Operating Income (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Non Operating Income for 15 consecutive years, with $375000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 18.3% year-over-year to $375000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 35.58% YoY), while the FY2025 annual figure was $1.9 million, up 69.44% from the prior year.
- Non Operating Income rose to $375000.0 in Q1 2026 per NAGE's latest filing, from $338000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $564000.0 in Q3 2025 and bottomed at $125000.0 in Q2 2023.
- Historically, Non Operating Income has averaged $334333.3 across 4 years, with a median of $310000.0 in 2023.
- Annual changes were most pronounced in 2025 — Non Operating Income surged 129.05% — and 2026, when it retreated 18.3%.
- Niagen Bioscience's Non Operating Income stood at $282000.0 in 2023, then jumped by 32.27% to $373000.0 in 2024, then slipped by 9.38% to $338000.0 in 2025, then climbed by 10.95% to $375000.0 in 2026.
- Business Quant data shows NAGE's Non Operating Income at $375000.0 in Q1 2026, $338000.0 in Q4 2025, and $564000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 372,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 372,000.00 |
| Mar 31, 2026 | 375,000.00 |
| Dec 31, 2025 | 338,000.00 |
| Sep 30, 2025 | 564,000.00 |
| Jun 30, 2025 | 552,000.00 |
| Mar 31, 2025 | 459,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 239,000.00 |
| Dec 31, 2023 | 282,000.00 |
| Sep 30, 2023 | 188,000.00 |
| Jun 30, 2023 | 125,000.00 |
| Jun 30, 2020 | -24,000.00 |
| Mar 31, 2020 | -12,000.00 |
| Dec 31, 2019 | 7,000.00 |
| Sep 30, 2019 | -314,000.00 |
| Jun 30, 2019 | -575,000.00 |
| Mar 31, 2019 | 35,000.00 |
| Dec 31, 2018 | 22,000.00 |